President Trump touted a $765 million loan Tuesday that will transform the former imaging giant Kodak into a pharmaceutical manufacturer

Follow us on social media

President Trump touted a $765 million loan Tuesday that will transform the former imaging giant Kodak into a pharmaceutical manufacturer

“It’s a breakthrough in bringing pharmaceutical manufacturing back to the United States,” Trump said at a press conference. “Kodak will now produce generic, active pharmaceutical ingredients. This is a big deal. Using advanced manufacturing techniques, Kodak will also make the key starting materials that are the building blocks for many drugs in a manner that is both cost competitive and environmentally safe.”

Shares of Kodak stock closed up more than 200 percent Tuesday.  Kodak said it will build out its headquarters at Eastman Business Park in Rochester, New York, and that the loan will create at least 360 jobs, while supporting an additional 1,200 indirectly.

The company used to be a technology giant. It employed more than 120,000 people worldwide in 1973, and invented the digital camera in 1975. Kodak failed to change with photography trends and it declared bankruptcy in 2012.

Despite that, Kodak Executive Chairman Jim Continenza said that the shift to pharmaceutical manufacturing makes sense for the company.

“Kodak is proud to be a part of strengthening America’s self-sufficiency in producing the key pharmaceutical ingredients we need to keep our citizens safe,” Continenza said in a statement. “By leveraging our vast infrastructure, deep expertise in chemicals manufacturing, and heritage of innovation and quality, Kodak will play a critical role in the return of a reliable American pharmaceutical supply chain.” 

The Trump administration says that Kodak will eventually produce 25 percent of America’s “generic active pharmaceutical ingredients necessary for all non-biologic and non-antibacterial pharmaceuticals.”

This isn’t Kodak’s first foray into the pharmaceutical industry. In 1988, the company established “a new health-care business with the establishment of its Eastman Pharmaceuticals Division.” It then bought Sterline Drug in 1988.

“Kodak acquired Sterling Drug Inc., providing the infrastructure and marketing ability Kodak needed to participate in markets for ethical/prescription and over-the-counter drugs,” according to the company website. “Kodak eventually sold its non-imaging health-related businesses in 1994.”

Kodak did not immediately respond to a request for comment Tuesday.

President Trump has invoked the Defense Production Act 33 times, which amounts to almost $3.2 billion in partnerships. During the coronavirus pandemic, he has used the DPA to ramp up the production of medical supplies like ventilators and masks.

“HHS, FEMA and the private sector combined have coordinated the delivery of more than 196,000,095 respirators, 815 million, 20 million gloves, 34 million face shields and 354 million gowns,” Trump said Tuesday.

Related Articles

COVID Reference

Six weeks after the third edition, the world has changed again.
The pandemic is raging in South America, particularly in Brazil,
Ecuador and Peru. SARS-CoV-2 is under control in China, but in
Iran it is not. And in Europe, where most countries have weathered
the first wave and open borders to save a compromised tourist season, is now wondering if and for how long this biological
drôle de guerre could last.

Science has moved ahead, too. We have seen a more complex
picture of COVID-19 and new clinical syndromes; the first data
from vaccine trials; first results from randomized controlled
drug studies; encouraging publications on monoclonal neutralizing antibodies and serological evidence about the number of people who have come into contact with SARS-CoV-2. Unfortunately, we have also seen the first science scandal with fake data published in highly ranked journals. And we face new challenges like long-term effects of COVID-19 and a Kawasaki-like inflammatory multisystem syndrome in children.

For quite some time, prevention will continue to be the primary
pillar of pandemic control. In future waves of the SARS-CoV-2
pandemic, we will focus on the conditions under which SARSCoV-
2 is best transmitted: crowded, closed (and noisy) places and
spaces. Although hospitals are not noisy, they are crowded and
closed, and the battle against the new coronavirus will be decided
at the very center of our healthcare system. Over the next
months and maybe years, one of all of our top priorities will be
to give all healthcare workers and patients perfect personal protective equipment.

The HPV Vaccine: An Ethical Dilemma

In 2014 there were numerous reports of mass hysteria and mystery illnesses spreading around the small town of El Carmen De Bolivar, Colombia. According to an article published by CBS, there was a steady increase of young women being hospitalized in this small town, all of which reported the same symptoms of fainting, numbness and tingling of the hands and feet, and headaches. Speculations about the Gardasil vaccination arose, but were disregarded by the mayor of the town stating that “there is no evidence the vaccine, which has undergone extensive testing and regulation is to blame” (CBS, 2014). According to this statement, he is not necessarily wrong, because the clinical trials of this vaccine have been proven to have misleading conclusions due to errors in the study design.

New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?

Recently, a novel coronavirus (2019-nCoV), officially known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in China. Despite drastic containment measures, the spread of this virus is ongoing. SARS-CoV-2 is the aetiological agent of coronavirus disease 2019 (COVID-19) characterised by pulmonary infection in humans. The efforts of international health authorities have since focused on rapid diagnosis and isolation of patients as well as the search for therapies able to counter the most severe effects of the disease. In the absence of a known efficient therapy and because of the situation of a public health emergency, it made sense to investigate the possible effect of chloroquine/hydroxychloroquine against SARS-CoV-2 since this molecule was previously described as a potent inhibitor of most coronaviruses, including SARS-CoV-1. Preliminary trials of chloroquine repurposing in the treatment of COVID- 19 in China have been encouraging, leading to several new trials. Here we discuss the possible mechanisms of chloroquine interference with the SARS-CoV-2 replication cycle.

Mass Exodus out of Big Cities on Both Coasts Taking Place

In all of U.S. history, we have never seen anything like “the mass exodus of 2020”. Hundreds of thousands of people are leaving the major cities on both coasts in search of a better life.  Homelessness, crime and drug use were already on the rise in many of our large cities prior to 2020, but many big-city residents were willing to put up with a certain amount of chaos in order to maintain their lifestyles.  However, the #COVID19 pandemic and months of #civilunrest have finally pushed a lot of people over the edge.  Moving companies on both coasts are doing a booming business as wealthy and middle-class families flee at a blistering pace, and most of those families do not plan to ever return.